Rep. Robert Bresnahan, Jr. Sells Thermo Fisher Scientific Inc. (NYSE:TMO) Stock

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of Thermo Fisher Scientific Inc. (NYSE:TMO). In a filing disclosed on April 28th, the Representative disclosed that they had sold between $15,001 and $50,000 in Thermo Fisher Scientific stock on April 8th. The trade occurred in the Representative’s “JP MORGAN BROKERAGE ACCOUNT” account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of DexCom (NASDAQ:DXCM) on 4/8/2025.
• Sold $1,001 – $15,000 in shares of Invesco (NYSE:IVZ) on 4/8/2025.
• Sold $1,001 – $15,000 in shares of Generac (NYSE:GNRC) on 4/8/2025.
• Sold $15,001 – $50,000 in shares of Occidental Petroleum (NYSE:OXY) on 4/8/2025.
• Sold $15,001 – $50,000 in shares of Pfizer (NYSE:PFE) on 4/8/2025.
• Sold $1,001 – $15,000 in shares of QUALCOMM (NASDAQ:QCOM) on 4/8/2025.
• Sold $1,001 – $15,000 in shares of Best Buy (NYSE:BBY) on 4/8/2025.
• Sold $1,001 – $15,000 in shares of EOG Resources (NYSE:EOG) on 4/8/2025.
• Sold $1,001 – $15,000 in shares of CSX (NASDAQ:CSX) on 4/8/2025.
• Sold $1,001 – $15,000 in shares of Valero Energy (NYSE:VLO) on 4/8/2025.

Thermo Fisher Scientific Trading Up 1.5 %

TMO opened at $427.56 on Wednesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. Thermo Fisher Scientific Inc. has a fifty-two week low of $409.85 and a fifty-two week high of $627.88. The firm has a market capitalization of $161.40 billion, a PE ratio of 25.87, a P/E/G ratio of 2.99 and a beta of 0.86. The company’s 50-day moving average is $482.87 and its 200 day moving average is $524.80.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping analysts’ consensus estimates of $5.10 by $0.05. The company had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The firm’s revenue was up .2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $5.11 EPS. As a group, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.40%. The ex-dividend date of this dividend was Friday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s dividend payout ratio is currently 10.09%.

Wall Street Analyst Weigh In

Several equities research analysts have commented on TMO shares. Raymond James reiterated an “outperform” rating and issued a $667.00 price objective (up previously from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Robert W. Baird decreased their price objective on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating for the company in a research note on Thursday, April 24th. Sanford C. Bernstein raised shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 target price for the company in a research report on Friday, January 10th. UBS Group reduced their target price on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating for the company in a research report on Thursday, April 24th. Finally, Barclays reduced their target price on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating for the company in a research report on Thursday, April 10th. Five equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average price target of $610.27.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $175,677.00. Following the completion of the transaction, the executive vice president now owns 16,363 shares of the company’s stock, valued at $9,582,009.17. This represents a 1.80 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the transaction, the chief executive officer now directly owns 115,174 shares of the company’s stock, valued at $59,506,950.58. The trade was a 7.99 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 23,900 shares of company stock worth $13,106,062 in the last ninety days. 0.33% of the stock is owned by company insiders.

Hedge Funds Weigh In On Thermo Fisher Scientific

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TMO. Bernard Wealth Management Corp. purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter worth about $25,000. Barrett & Company Inc. purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter worth about $28,000. FPC Investment Advisory Inc. purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter worth about $28,000. Pillar Financial Advisors LLC purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter worth about $29,000. Finally, Missouri Trust & Investment Co purchased a new stake in Thermo Fisher Scientific during the 4th quarter valued at about $29,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 8th Congressional District. He declared candidacy for the 2026 election.

Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.